MULTIPLAN CORP (MPLN) Stock Fundamental Analysis

NYSE:MPLN • US62548M2098

23.15 USD
-0.36 (-1.53%)
At close: Feb 27, 2025
23.15 USD
0 (0%)
After Hours: 2/27/2025, 8:04:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

Taking everything into account, MPLN scores 2 out of 10 in our fundamental rating. MPLN was compared to 35 industry peers in the Health Care Technology industry. MPLN has a bad profitability rating. Also its financial health evaluation is rather negative. MPLN has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

3

1. Profitability

1.1 Basic Checks

  • In the past year MPLN has reported negative net income.
  • In the past year MPLN had a positive cash flow from operations.
  • MPLN had negative earnings in 4 of the past 5 years.
  • MPLN had a positive operating cash flow in each of the past 5 years.
MPLN Yearly Net Income VS EBIT VS OCF VS FCFMPLN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 -500M -1B -1.5B

1.2 Ratios

  • MPLN has a Return On Assets (-31.95%) which is comparable to the rest of the industry.
  • MPLN has a Return On Equity of -1958.81%. This is amonst the worse of the industry: MPLN underperforms 81.58% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 1.58%, MPLN is in the better half of the industry, outperforming 76.32% of the companies in the same industry.
  • The Average Return On Invested Capital over the past 3 years for MPLN is below the industry average of 6.72%.
Industry RankSector Rank
ROA -31.95%
ROE -1958.81%
ROIC 1.58%
ROA(3y)-13.68%
ROA(5y)-9.22%
ROE(3y)-665.39%
ROE(5y)-402.43%
ROIC(3y)2.41%
ROIC(5y)N/A
MPLN Yearly ROA, ROE, ROICMPLN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

1.3 Margins

  • MPLN's Operating Margin of 10.63% is amongst the best of the industry. MPLN outperforms 92.11% of its industry peers.
  • In the last couple of years the Operating Margin of MPLN has declined.
  • MPLN's Gross Margin of 74.27% is amongst the best of the industry. MPLN outperforms 84.21% of its industry peers.
  • In the last couple of years the Gross Margin of MPLN has declined.
Industry RankSector Rank
OM 10.63%
PM (TTM) N/A
GM 74.27%
OM growth 3Y-33.57%
OM growth 5Y-22.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.14%
GM growth 5Y-2.61%
MPLN Yearly Profit, Operating, Gross MarginsMPLN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), MPLN is destroying value.
  • The number of shares outstanding for MPLN remains at a similar level compared to 1 year ago.
  • Compared to 5 years ago, MPLN has less shares outstanding
  • The debt/assets ratio for MPLN is higher compared to a year ago.
MPLN Yearly Shares OutstandingMPLN Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 200M 400M 600M
MPLN Yearly Total Debt VS Total AssetsMPLN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B

2.2 Solvency

  • MPLN has an Altman-Z score of -0.30. This is a bad value and indicates that MPLN is not financially healthy and even has some risk of bankruptcy.
  • MPLN's Altman-Z score of -0.30 is in line compared to the rest of the industry. MPLN outperforms 47.37% of its industry peers.
  • A Debt/Equity ratio of 53.67 is on the high side and indicates that MPLN has dependencies on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 53.67, MPLN is doing worse than 81.58% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 53.67
Debt/FCF N/A
Altman-Z -0.3
ROIC/WACC0.25
WACC6.29%
MPLN Yearly LT Debt VS Equity VS FCFMPLN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 1B 2B 3B 4B 5B

2.3 Liquidity

  • A Current Ratio of 0.82 indicates that MPLN may have some problems paying its short term obligations.
  • MPLN has a worse Current ratio (0.82) than 76.32% of its industry peers.
  • MPLN has a Quick Ratio of 0.82. This is a bad value and indicates that MPLN is not financially healthy enough and could expect problems in meeting its short term obligations.
  • The Quick ratio of MPLN (0.82) is worse than 71.05% of its industry peers.
Industry RankSector Rank
Current Ratio 0.82
Quick Ratio 0.82
MPLN Yearly Current Assets VS Current LiabilitesMPLN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • The earnings per share for MPLN have decreased strongly by -1059.83% in the last year.
  • The Revenue has decreased by -3.21% in the past year.
  • MPLN shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -1.09% yearly.
EPS 1Y (TTM)-1059.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-327%
Revenue 1Y (TTM)-3.21%
Revenue growth 3Y-5.92%
Revenue growth 5Y-1.09%
Sales Q2Q%-4.9%

3.2 Future

  • Based on estimates for the next years, MPLN will show a very strong growth in Earnings Per Share. The EPS will grow by 36.67% on average per year.
  • MPLN is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.09% yearly.
EPS Next Y87.02%
EPS Next 2Y36.67%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year0.75%
Revenue Next 2Y2.09%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
MPLN Yearly Revenue VS EstimatesMPLN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 200M 400M 600M 800M 1B
MPLN Yearly EPS VS EstimatesMPLN Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 0 -20 -40 -60 -80

More info and screens

Find the best growth stocksShow best growing peers

2

4. Valuation

4.1 Price/Earnings Ratio

  • MPLN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year MPLN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MPLN Price Earnings VS Forward Price EarningsMPLN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of MPLN indicates a rather cheap valuation: MPLN is cheaper than 94.74% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 9.19
MPLN Per share dataMPLN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -100 -200

4.3 Compensation for Growth

  • A more expensive valuation may be justified as MPLN's earnings are expected to grow with 36.67% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.67%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • MPLN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

MULTIPLAN CORP

NYSE:MPLN (2/27/2025, 8:04:01 PM)

After market: 23.15 0 (0%)

23.15

-0.36 (-1.53%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)02-25
Earnings (Next)05-06
Inst Owners47.86%
Inst Owner Change-26.45%
Ins Owners6%
Ins Owner Change0%
Market Cap375.03M
Revenue(TTM)930.62M
Net Income(TTM)-1.65B
Analysts77.78
Price Target13.94 (-39.78%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-29.46%
Min EPS beat(2)-73.58%
Max EPS beat(2)14.65%
EPS beat(4)2
Avg EPS beat(4)-370.31%
Min EPS beat(4)-1467.36%
Max EPS beat(4)45.02%
EPS beat(8)5
Avg EPS beat(8)-168.93%
EPS beat(12)6
Avg EPS beat(12)-282.74%
EPS beat(16)9
Avg EPS beat(16)-181.58%
Revenue beat(2)0
Avg Revenue beat(2)-3.09%
Min Revenue beat(2)-3.29%
Max Revenue beat(2)-2.88%
Revenue beat(4)0
Avg Revenue beat(4)-4.72%
Min Revenue beat(4)-6.88%
Max Revenue beat(4)-2.88%
Revenue beat(8)2
Avg Revenue beat(8)-2.62%
Revenue beat(12)3
Avg Revenue beat(12)-3.01%
Revenue beat(16)6
Avg Revenue beat(16)-1.99%
PT rev (1m)26.15%
PT rev (3m)24.24%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-25.28%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.98%
Revenue NQ rev (1m)-0.56%
Revenue NQ rev (3m)2.01%
Revenue NY rev (1m)-0.41%
Revenue NY rev (3m)-0.42%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.4
P/FCF N/A
P/OCF 3.48
P/B 4.46
P/tB N/A
EV/EBITDA 9.19
EPS(TTM)-69.59
EYN/A
EPS(NY)-9.03
Fwd EYN/A
FCF(TTM)-0.65
FCFYN/A
OCF(TTM)6.64
OCFY28.7%
SpS57.45
BVpS5.19
TBVpS-280.58
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -31.95%
ROE -1958.81%
ROCE 2%
ROIC 1.58%
ROICexc 1.59%
ROICexgc 26.88%
OM 10.63%
PM (TTM) N/A
GM 74.27%
FCFM N/A
ROA(3y)-13.68%
ROA(5y)-9.22%
ROE(3y)-665.39%
ROE(5y)-402.43%
ROIC(3y)2.41%
ROIC(5y)N/A
ROICexc(3y)2.48%
ROICexc(5y)N/A
ROICexgc(3y)66.67%
ROICexgc(5y)N/A
ROCE(3y)3.05%
ROCE(5y)N/A
ROICexgc growth 3Y-40.96%
ROICexgc growth 5Y-27.14%
ROICexc growth 3Y-26.84%
ROICexc growth 5Y-14.89%
OM growth 3Y-33.57%
OM growth 5Y-22.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.14%
GM growth 5Y-2.61%
F-Score3
Asset Turnover0.18
Health
Industry RankSector Rank
Debt/Equity 53.67
Debt/FCF N/A
Debt/EBITDA 8.49
Cap/Depr 27.34%
Cap/Sales 12.69%
Interest Coverage 0.31
Cash Conversion 20.27%
Profit Quality N/A
Current Ratio 0.82
Quick Ratio 0.82
Altman-Z -0.3
F-Score3
WACC6.29%
ROIC/WACC0.25
Cap/Depr(3y)25.06%
Cap/Depr(5y)22.79%
Cap/Sales(3y)10.77%
Cap/Sales(5y)9.49%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1059.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-327%
EPS Next Y87.02%
EPS Next 2Y36.67%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-3.21%
Revenue growth 3Y-5.92%
Revenue growth 5Y-1.09%
Sales Q2Q%-4.9%
Revenue Next Year0.75%
Revenue Next 2Y2.09%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-41.76%
EBIT growth 3Y-37.5%
EBIT growth 5Y-23.25%
EBIT Next Year144.41%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-116.71%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-37.33%
OCF growth 3Y-35.69%
OCF growth 5Y-17.66%

MULTIPLAN CORP / MPLN FAQ

Can you provide the ChartMill fundamental rating for MULTIPLAN CORP?

ChartMill assigns a fundamental rating of 2 / 10 to MPLN.


What is the valuation status of MULTIPLAN CORP (MPLN) stock?

ChartMill assigns a valuation rating of 2 / 10 to MULTIPLAN CORP (MPLN). This can be considered as Overvalued.


What is the profitability of MPLN stock?

MULTIPLAN CORP (MPLN) has a profitability rating of 3 / 10.